São Paulo officials present CoronaVac efficacy rates. Photo: GOVESP
The Brazilian National Health Surveillance Agency (Anvisa) received a request for the emergency approval of Chinese-made coronavirus vaccine CoronaVac on Friday. The petition was filed by São Paulo’s Butantan Institute — which carried out CoronaVac clinical trials in Brazil — following a deal with the federal government for 100 million doses.
Anvisa officials say clearance could come within ten days — but the agency may extend the deadline if further information is necessary.
On January 7, Butantan announced that CoronaVac has a 78-percent efficacy rate against mild Covid-19 infections — and 100 percent for severe cases. However, the institute offered no further details on the clinical trial results.
Support this coverage →The São Paulo City Council on Thursday approved legislation authorizing Brazil’s largest city to sign…
The preliminary report on AI regulations presented to Brazil’s Senate last week provides a middle-of-the-road…
In 2000, Formula 1 great Michael Schumacher had just racked up his 41st race win,…
Overall, the worldwide economic outlook has improved according to the Organization for Economic Co-operation and…
“This is f***ing corruption, it has to change,” protested an irate John Textor, owner of…
Eduardo Leite, governor of the southern Brazilian state of Rio Grande do Sul, on Wednesday…